Stratatech received a BARDA contract in July 2013 for their artificial skin that uses a tissue derived scaffold/matrix
as opposed to a synthetic scaffold used by Polynovo.
http://www.stratatechcorp.com/news/20130731.php
http://www.stratatechcorp.com/news/index.php
Since this announcement nothing has been said as to development progress for the product. Polynovo have eight US burns clinics supporting their BARDA contract application. In view of the apparent lack of progress from Stratatech a contract of similar size could be possible for Polynovo. It is after all in the clinic at the Adelaide Hospital burns trial
putting Polynovo further down the track to proof on concept and commercialization.
http://www.advisory.com/Research/Se...es-potential-promise-of-regenerative-medicine
A couple of interesting quotes
"Though the StrataGraft product does not represent a significant improvement of care, producing outcomes comparable to the current standard of care for complex skin defects"
"Though StrataGraft may not reach the bedside for some time, if at all, engineered tissue like has a strong potential to revolutionize medicine in the years to come". The highlighted comment more likely to apply to Novoskin, I think Dr Greenwood has said as much!!
- Forums
- ASX - By Stock
- PNV
- Is BARDA still looking??
Is BARDA still looking??
Featured News
Add PNV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.02 |
Change
-0.040(1.94%) |
Mkt cap ! $1.395B |
Open | High | Low | Value | Volume |
$2.01 | $2.04 | $2.00 | $1.537M | 762.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 41008 | $2.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.03 | 5942 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 41008 | 2.010 |
3 | 3707 | 2.000 |
2 | 4936 | 1.995 |
2 | 9435 | 1.990 |
2 | 10000 | 1.985 |
Price($) | Vol. | No. |
---|---|---|
2.030 | 5942 | 2 |
2.040 | 73942 | 4 |
2.050 | 6539 | 2 |
2.060 | 23114 | 3 |
2.100 | 7200 | 1 |
Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |